The Drug Enforcement Administration announced on July 1, 2026 its intent to temporarily place 7-hydroxymitragynine (7-OH), a kratom-derived opioid-like compound, and three related substances into Schedule I of the Controlled Substances Act, per the DEA, 2026. The notice of intent was published in the Federal Register on July 6, 2026 — a move that lands directly on a wellness-industry niche selling 7-OH drinks, gummies, and shots.
This site publishes information, not medical or legal advice. Temporary scheduling is a policy action with a public-health rationale, not a final legal verdict on any product or seller, and the scheduling begins a review that could change. If you use kratom or 7-OH products and feel dependent or unwell, talk with a clinician — stopping opioids abruptly can be dangerous.
What is 7-OH and why act now?
7-OH is a compound that occurs naturally in kratom leaf in trace amounts but is concentrated in many newer products — shots, drink mixes, and gummies sold in wellness and vape shops, per the FDA, 2026. The FDA, which had pressed for restrictions, warned companies against marketing products containing concentrated 7-OH and issued warning letters to seven firms for illegally marketing such products, per the FDA. HHS and FDA publicly supported the DEA's scheduling action, per HHS.
Important nuance for the industry: the federal action targets concentrated or synthetic 7-OH, not natural kratom leaf itself, which remains legal federally — though states regulate it separately, per the DEA, 2026.
Related stories: Hims & Hers Posts $2.35B Year as GLP-1 Scrutiny Grows · FTC Finalizes $4M Order Against Kids' Height Supplements.
What happens to businesses selling 7-OH products?
Schedule I placement means a substance is treated as having no currently accepted medical use and a high potential for dependence, making sale a federal controlled-substances issue, per the DEA, 2026. Sellers face choices already familiar from earlier regulatory waves: pull 7-OH inventory, reformulate around plain kratom leaf where legal, or pivot entirely. Retailers who stocked 7-OH drinks as a wellness category now face compliance questions their suppliers may not answer.
What this changes for readers
If you buy energy or relaxation drinks with botanical ingredients, check labels for "7-hydroxymitragynine" or "7-OH." After the temporary listing takes effect, products built around it are not wellness items in any meaningful sense — they contain a federally scheduled substance, per the DEA, 2026. And if you have been using 7-OH products daily, mention it to a clinician before stopping on your own.
The bottom line
Per the DEA, July 1, 2026, 7-OH and three related substances face temporary Schedule I scheduling, published in the Federal Register on July 6, 2026, after FDA pressure and warning letters to seven companies, per the FDA. The 7-OH wellness-drink niche now faces a federal deadline; readers should check labels and involve a clinician before changing use.